| Similar Articles |
|---|
 |
The Motley Fool
September 28, 2006
Brian Lawler |
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.   |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap. |
The Motley Fool
April 28, 2008
Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. |
The Motley Fool
April 24, 2007
Brian Lawler |
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices. |
The Motley Fool
July 30, 2007
Brian Lawler |
Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note. |
The Motley Fool
January 28, 2008
Brian Lawler |
A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note. |
BusinessWeek
June 4, 2007
Gene G. Marcial |
Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
The Motley Fool
May 29, 2007
Brian Lawler |
Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note. |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either. |
The Motley Fool
July 21, 2005
Tom Taulli |
Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey. |
The Motley Fool
January 27, 2009
Brian Orelli |
Amgen's Anemic Again 2009 won't be stellar, but the future looks better. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
The Motley Fool
July 28, 2008
Brian Lawler |
Amgen's Bone-Building Boost The drugmaker gets good news about a top pipeline compound. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
BusinessWeek
March 22, 2004
Arlene Weintraub |
Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work? |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
August 11, 2010
Brian Orelli |
Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough. |
The Motley Fool
November 9, 2006
Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. |
The Motley Fool
November 17, 2006
Brian Lawler |
Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note. |
The Motley Fool
October 24, 2006
Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. |
The Motley Fool
February 9, 2010
Brian Orelli |
Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status. |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
April 21, 2011
Luke Timmerman |
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis. |
The Motley Fool
July 28, 2009
Brian Orelli |
Amgen Secures Its Future Earnings and a marketing partnership -- oh my. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 15, 2007
Brian Lawler |
Amgen vs. Intel: Amgen In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Why Amgen deserves to win this match-up. |
The Motley Fool
March 23, 2004
David Nierengarten |
Genentech's Star Power How much higher can Genentech go? |
The Motley Fool
April 20, 2010
Jim Mueller |
Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors. |
The Motley Fool
October 22, 2009
Brian Orelli |
Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia. |
The Motley Fool
September 25, 2007
Brian Lawler |
Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note. |
BusinessWeek
May 15, 2006
Arlene Weintraub |
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors. |
The Motley Fool
October 30, 2007
Brian Lawler |
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results. |
The Motley Fool
June 7, 2007
Brian Lawler |
Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline. |
The Motley Fool
January 25, 2008
Brian Lawler |
Amgen: Punched Out or Still Fighting? Amgen manages to pull off a 3.5% increase in revenue for 2007, even with sales of its anemia franchise drugs Aranesp and Epogen down a combined 17% year over year in the fourth quarter. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
February 27, 2004
Alyce Lomax |
Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today. |
The Motley Fool
August 1, 2007
Brian Lawler |
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth. |
The Motley Fool
February 9, 2011
Luke Timmerman |
Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"? |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
August 19, 2009
Brian Orelli |
Amgen's Climbing Up the Ladder Positive trial data should help sales. |
The Motley Fool
November 19, 2010
Brian Orelli |
One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales. |
BusinessWeek
January 14, 2010
Rob Waters |
Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology. |
